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TOPICS IN JOINT MODELING OF LONGITUDINAL BIOMARKER,
QUALITY OF LIFETIME, AND SURVIVAL DATA
Xinxin Dong, PhD
University of Pittsburgh, 2013
ABSTRACT: Joint modeling techniques have been developed for analyzing correlated lon-
gitudinal and survival data in many studies. It provides consistent and efficient estimates
of the parameters even when the longitudinal covariate is measured infrequently and with
measurement error. This work focuses on the use of joint modeling to solve two different
statistical problems. The first one is about analyzing censored biomarker measurements
and survival data under a case-cohort design. The goal is to study how the biomarker level
changes over time, and the relationship between longitudinal biomarker measurements and
the event time. We suggest a modified likelihood-based approach to adjust the possible bias
introduced by the censoring due to detection limits and the measurement error in biomarker
measurements. The second topic is about drawing inference for mean quality adjusted life-
time data. We consider continuous health experience and define the quality function with
repeatedly measured quality of life score. We propose a consistent and asymptotic normal
estimate for the mean quality adjusted lifetime and derive its asymptotic variance. The
performances of the proposed methods have been demonstrated in simulation studies and
through real data examples.
Public Health Significance: A case-cohort study is a cost-effective design that is used in
many large epidemiological studies. The method proposed in the first part of this dissertation
increases the efficiency of the parameter estimation under case-cohort designs, which can
lead to a considerable reduction in cost and effort. The evaluation of health benefits is a
major public health challenge. The second part of this dissertation presents the estimate of
iv
mean quality adjusted lifetime, which can serve as a measurement of health benefits in the
comparison of treatments or public health strategies.
Keywords: Joint analysis, Case-cohort, Longitudinal biomarker, Limit of detection (LOD),
Mixed effects model, Accelerated failure time model, Quality of life, Survival analysis.
v
TABLE OF CONTENTS
PREFACE . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . x
1.0 INTRODUCTION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
2.0 ACCELERATED FAILURE TIME MODEL FOR CASE-COHORT DE-
SIGN WITH LONGITUDINAL COVARIATES SUBJECT TO MEA-
SUREMENT ERROR AND DETECTION LIMITS . . . . . . . . . . . . 3
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
2.2 Notation and Model Specifications . . . . . . . . . . . . . . . . . . . . . . . 6
2.3 Inference procedure under a case-cohort design . . . . . . . . . . . . . . . . 8
2.4 Simulation Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.5 Application . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
2.6 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
3.0 INFERENCE FOR MEAN QUALITY ADJUSTED LIFETIME WITH
QUALITY OF LIFE MEASURED REPEATEDLY WITH ERROR . . 22
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 22
3.2 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.2.1 Set-up . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
3.2.2 Observed Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
3.3 Inference . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.3.1 Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
3.3.1.1 Model for the longitudinal QOL score . . . . . . . . . . . . . . 27
3.3.1.2 Model for the survival time . . . . . . . . . . . . . . . . . . . 28
3.3.1.3 Estimation of β . . . . . . . . . . . . . . . . . . . . . . . . . . 28
vi
3.3.2 Estimation of mean QAL . . . . . . . . . . . . . . . . . . . . . . . . . 29
3.3.3 Consistency of µˆ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.4 Simulation Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.5 Conclusion and Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
BIBLIOGRAPHY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
vii
LIST OF TABLES
1 Simulation results for β under model M1 where T0 follows a Weibull distribu-
tion with 500 replications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
2 Simulation results for β under model M2 where T0 follows an Exponential
distribution with 500 replications. . . . . . . . . . . . . . . . . . . . . . . . . 15
3 Simulation results for β under model M3 where T0 follows Exponential distri-
bution with 500 replications. . . . . . . . . . . . . . . . . . . . . . . . . . . . 16
4 Akaike information criterion (AIC) and Bayesian information criterion (BIC)
values for joint analysis of a linear mixed effects model with random intercept
and an AFT model adjusted for gender, race and ICU use. . . . . . . . . . . 19
5 Joint analysis of log transformed cytokine IL6 trajectory vs 90-day mortality
adjusting for gender, race and ICU use in GenIMS study . . . . . . . . . . . . 19
6 Simulation results for the estimator of the mean quality adjusted lifetime,
µˆ, and its asymptotic standard error for 20% censored data based on 500
replications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 39
7 Simulation results for the estimator of the mean quality adjusted lifetime,
µˆ, and its asymptotic standard error for 40% censored data based on 500
replications. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
viii
LIST OF FIGURES
1 Boxplots for log transformed IL-6 by survival and mortality groups . . . . . . 20
ix
PREFACE
It is difficult to overstate my sincere gratitude to my thesis advisor, Dr. Abdus Wahed. I
greatly thank him for his inspiration, patience, and encouragement. I enjoyed the meetings
with him and was always benefited from his insightful comments and suggestions. I also own
my deepest gratitude to my former advisor, Dr. Lan Kong. She made herself available when-
ever I needed her and extended abundant time and effect to help me write the manuscript
and guide me with patience. I was fortunate to have Dr. Carol Redmond as my master ad-
visor and committee member for the PhD dissertation. She taught me not only professional
knowledge, but also how to be a good researcher. I am indebted to Dr. Joyce Chang in
many ways. Being a teaching assistant for her class provided me with a valuable opportunity
to learn the presentation skills from the best, and the Graduate Student Researcher (GSR)
position she recommended helped me gain extremely precious research experience. I would
like to acknowledge Dr. Douglas Landsittel for carefully reading my thesis, and giving me
helpful suggestions about the practical use of the methodologies. His input has improved
this dissertation and also inspired ideas for future research direction.
I am grateful to all the faculty members, colleagues and friends in the Department of
Biostatistics at the University of Pittsburgh. They have made a significant impact on my
professional growth. What I learned from them will be a lifetime treasure.
Finally, much gratitude is owed to my parents and husband for all of their love, support
and encouragement.
x
1.0 INTRODUCTION
In the first part of this dissertation, we describe a joint analysis approach for biomarker and
survival data under a case-cohort design. Biomarkers are often measured over time in epi-
demiological studies and clinical trials for understanding better the mechanism of diseases.
In large cohort studies, case-cohort sampling provides a cost effective method to collect ex-
pensive biomarker data for revealing the relationship between biomarker trajectories and
time to event. However, biomarker measurements are often limited by the sensitivity and
precision of a given assay, resulting in data that are censored at detection limits and prone to
measurement errors. Additionally, occurrence of an event of interest may proclude biomark-
ers from being further evaluated. Inappropriate handling of these types of data can lead to
biased estimates or errorneous conclusions. Under a classical case cohort design, we propose
a modified likelihood-based approach to accommodate these special features of longitudi-
nal biomarker measurements in the accelerated failure time (AFT) models. The maximum
likelihood estimators based on the full likelihood function are obtained by the Gaussian
quadrature method. We evaluate the performance of our case-cohort estimator and compare
its relative efficiency to the full cohort estimator through simulation studies. The proposed
method is further illustrated using the data from a biomarker study of sepsis among patients
with community acquired pneumonia.
The second part of this dissertation focuses on quality adjusted lifetime, which has be-
come important measure for treatment evaluation in clinical trials or observational studies to
quantify health benefits. Zhao and Tsiatis (2000) [63] derived a class of estimators and their
asymptotic variances for mean quality adjusted lifetime for right-censored survival data. In
their consideration, the quality function was assumed to be a known piecewise constant func-
tion where the quality remains constant within the same state. Consequently, they defined
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the quality adjusted lifetime as a weighted sum (integral) of the times spent at each health
state until the event of interest or censoring. However, in many applications quality of life
is repeatedly measured using instruments over time and hence the actual quality function is
unknown and ususally estimated by fitting some non-linear model over time. We consider in-
ference on mean quality adjusted lifetime (QAL) when the quality function is estimated from
the data. Specifically, we propose an estimator of the mean QAL and establish its asymptotic
properties. The proposed estimator is shown to be consistent and asymptotically normal.
The estimator of its asymptotic variance is also derived. The practical performance of the
proposed estimator is illustrated via a simulation study.
2
2.0 ACCELERATED FAILURE TIME MODEL FOR CASE-COHORT
DESIGN WITH LONGITUDINAL COVARIATES SUBJECT TO
MEASUREMENT ERROR AND DETECTION LIMITS
2.1 INTRODUCTION
Longitudinal measurements collected along with time-to-event information have become an
important data component in many epidemiological and clinical studies. Common objectives
of such studies are to examine how the longitudinal variables vary over time, and how
they correlate with the event of interest. For instance, a panel of biological markers is
often measured over time to understand better the mechanism of a disease and aid in the
development of effective treatments. In vaccine studies, immune responses are evaluated
repeatedly to see if they can serve as surrogate markers for the study endpoint which takes a
long time to be observed. Marker information for environmental exposure is assembled over
time to study how the history of being exposed to certain chemical materials is associated
with the risk of an occupational disease. Our motivating example, Genetic and Inflammatory
Markers of Sepsis (Kellum et al., 2007) [25] study, focused on understanding the natural
history and development of sepsis, and identifying the biomarkers indicating the risk for
severe sepsis, multiple organ failure, and death. A set of inflammatory and coagulation
markers from blood samples were evaluated repeatedly during the course of hospitalization,
and one of the primary outcomes was 90-day mortality since enrollment.
In some large cohort studies, it is prohibitive to analyze multiple biomarkers over time
for each individual although the biological samples can be collected for all subjects in the
cohort. A cost effective solution is the case-cohort design (Prentice, 1986) [40], where a
random sample, namely subcohort, is selected from a well-defined cohort at the beginning of
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the study. Covariate data of interest are collected for all subjects in this subcohort and those
who develop the event of interest outside the subcohort. Compared with full-cohort study, a
case-cohort design leads to significant reductions in cost and effort, especially when the event
of interest is rare and/or exposures are expensive to ascertain. It is also flexible for analyzing
multiple outcomes of interest by using the subcohort as the common comparison group. The
Atherosclerosis Risk in Communities study (The ARIC Investigators, 1989) [49] used a case-
cohort design to investigate certain plasma/genetic markers as risk factors of coronary heart
disease (CHD) and stroke. The Busselton Health study [10], a large Australian cohort study,
applied case-cohort sampling to study the association between serum markers and CHD and
stroke events to reduce costs and preserve stored serum.
Time-to-event data under a case-cohort design have been extensively studied using the
proportional hazards (PH) model (Cox, 1972) [9]. A pseudo-likelihood approach for inference
from the PH model has been proposed by Prentice (1986) [40], and further investigated by
Self and Prentice (1988) [45], and Lin and Ying (1993) [32]. Variance estimators in the
PH model have been presented by Wacholder et al. (1989) [56] and Barlow (1994) [3].
Computational issues have been described and addressed by Therneau and Li (1999) [50],
Langholz and Jiao (2007) [31]. Improved estimators have been derived by Chen and Lo
(1999) [6], Borgan et al. (2000) [4], Chen (2001a) [7], and Samuelsen et al. (2007) [44].
Sorensen and Anderson (2000) [47] considered a competing risk model for case-cohort data.
Non-proportional hazard models have also been studied under a case-cohort design, for
example, Kulich and Lin (2000) [30], Sun et al. (2004) [48], and Ma (2007) [37] proposed an
additive hazards model. Chen (2001b) [5], Kong et al. (2004) [27], Lu and Tsiatis (2006)
[35] considered semiparametric transfromation models. Nan et al. (2006) [38], Kong and
Cai (2009) [26] studied the case-cohort data under accelerated failure time models. Lu and
Shih (2006) [35], and Zhang et al. (2011) [61] proposed methods to accommodate clustered
survival data. Kang and Cai (2009) [28] considered multiple events under a case-cohort
design.
Longitudinal variables can be incorporated into survival models as time-dependent co-
variates, if they were measured without error and complete histories were known. Chal-
lenges arise, however, because biomarker information are usually collected intermittently,
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interrupted by the event time, and often subject to measurement error. Furthermore, due to
the sensitivity and precision of a given assay, biomarker measurements are censored by limit
of detection (LOD) when the concentrations are higher or lower than certain thresholds.
Given this nature of longitudinal data, joint modeling with a modified likelihood function
accounting for censoring due to LOD could be an ideal approach to examine if the expo-
sure trajectory (time-dependent covariate) influences the survival outcome. Joint analysis
of time-to-event and longitudinal data has been considered by Faucett and Thomas (1996)
[12], Hogan and Laird (1997a, 1997b, 1998) [20] [21], Wulfsohn and Tsiatis (1997) [58], Hen-
derson et al. (2000) [19], Hsieh et al. (2006) [22] and Vonesh et al. (2006) [55], among many
others. Under a nested case-control design, Tseng and Liu (2009) [51] linked a mixed-effect
model with a Cox model by shared latent random effects. Inference is drawn based on the
maximum likelihood method and is applicable to a case-cohort design. Most of the joint
modeling papers have focused on the use of Cox proportional hazards model to study the
association between repeated measures and survival information. However, there are two
main limitations of the Cox model: 1) the interpretation of covariate effect is not directly on
the survival time, but through the hazard function which may not be intuitive to the clinical
investigators; and 2) proportionality of hazards may not hold true in some applications.
An accelerated failure time (AFT) model (Cox, 1972) is an attractive alternative due to
its appealing interpretation and robustness to non-proportionality. It can be considered as
a log linear model that links the log transformed survival time to a set of covariates by a
linear regression model. The role of covariates can be interpreted as either accelerating or
decelerating the time to event. Tseng et al. (2005) [52] proposed a joint model of accelerated
failure time and longitudinal data for a full cohort study. We considered applying joint
modeling approach to case-cohort studies by using a linear mixed effects model to describe
the trajectory of longitudinal covariates, and an accelerated failure time model to investigate
the relationship between survival outcomes and longitudinal covariates subject to detection
limits. There are several advantages of our proposed method: 1) the model we use to describe
the covariate process allows the variation of population means over time, the unobserved
heterogeneity among subjects and possible additive measurement errors; 2) we efficiently use
all available information by incorporating the survival and covariate information of subjects
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who have longitudinal measurements missing by design; and 3) the likelihood we propose
accounts for longitudinal biomarkers data censored due to detection limits. Our estimation
procedure can be easily implemented when the baseline hazard function is specified. We
apply the Gaussian quadrature method through NLMIXED procedure in SAS to obtain
the maximum likelihood estimates for parameters in both longitudinal and survival models
simultaneously.
In Section 2.2 we introduce the details of our model specifications. Section 2.3 presents
the joint likelihood and estimation procedure. Section 2.4 describes the results from simula-
tion studies. Section 2.5 illustrates the method using the biomarker data from the Genetic
and Inflammatory Markers of Sepsis (GenIMS) study. Finally, Section 2.6 provides discussion
and concluding remarks.
2.2 NOTATION AND MODEL SPECIFICATIONS
Suppose that the full study cohort includes N subjects. For individual i, let Ti, Ci, and Xi be
the event time, the potential right censoring time, and the baseline covariate vector, respec-
tively. Due to censoring, we observe (Yi,∆i, Xi), where the time on study Yi = min(Ti, Ci)
and the event indicator 4i = 1, if Ti ≤ Ci, and 0 otherwise. At the beginning of the study, a
random sample, namely subcohort, is selected from the entire cohort. The case-cohort sub-
jects comprise this subcohort and all other cases. Let Ri = 1 if the ith individual is in the
case-cohort; and Ri = 0, otherwise. For individuals with Ri = 1, the longitudinal covariate
process, Zi(t), is measured at ti = {tij, j = 1, . . . ,mi}, for timi ≤ Yi, with measurement error
i = {ij, j = 1, . . . ,mi}.
Let Wij = Zi(tij) + ij be the observed measurement of covariate Z at time tij for the ith
subject. We postulate a linear mixed effects model for the observed longitudinal covariate
Wij as
Wij = b
T
i Gij + η
TX∗ij + ij, (2.1)
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where Gij is the subject specific design vector for the random effect bi, X
∗
ij is the design vector
for the fixed effects which might contain individual baseline covariates and the measurement
times tij, and ij’s are the measurement errors, assumed to be independently normally dis-
tributed with mean zero and variance σ2. Generally, the random effect bi’s are also assumed
to be normally distributed with mean zero and covariance matrix Σ and they are indepen-
dent of the measurement errors ij’s. Model (3.3) is the simple linear mixed effects model
that accounts for within subjects correlation through subject-specific random effects, and
the fixed parameters of this model allow assessment of change in the longitudinal biomarker
process over time. More complicated models, e.g. models that incorporate baseline covariate
and time interaction, can be considered in a similar fashion.
Due to the sensitivity of a given instrument, Wij is measurable within a detectable
range and can be censored by the lower and upper limits of detection, denoted by τl
and τu, respectively. Let di = {dij, j = 1, . . . ,mi} be the censoring indicator vector
for longitudinal measurements, then dij = 0 if τl ≤ Wij ≤ τu; 1 if Wij < τl; and 2
if Wij > τu. Therefore, the observed data for subject i can be written in the form of
(Yi,∆i, Xi, Ri, Ri{W I(dij=0)ij τ I(dij=1)l τ I(dij=2)u , j = 1, 2, . . . ,mi}, Riti), i = 1, 2, ..., n.
To evaluate the risk factors of time to event outcome, accelerated failure time (AFT)
model provides an important alternative to Cox regression model because it models the
failure time directly and allows non-proportionality of hazards. If the covariates are time-
invariant, AFT model relates the natural logarithm of event time to a set of covariates by a
linear regression model,
log(Ti) = −β′Xi + i, (2.2)
where β is an unknown vector of regression coefficients, β′ denotes the transpose of β, and
i’s are independently and identically distributed random errors. Let T0 be the event time
variable at X = 0, then Ti = T0 exp(−β′Xi) where T0 = exp(). Suppose S0(t) is the survival
function of T0, which is also referred to as baseline survival function. Model (2.2) implies
that the survival function of T at given covariate vector X is S(t|X) = S0(t exp{β′X}).
Thus, the covariate in AFT model has a multiplicative effect on the failure time rather than
on the hazard function as in the Cox regression models.
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To evaluate the effect of the longitudinal process on the event time, we use the extension
of an AFT model for time-dependent covariates suggested by Cox and Oakes (1984). Define
the ”covariate history” up to t as H¯i(t, bi) = {Hi(s, bi), s < t} where Hi(s, bi) = {Xi, Zi(s)}.
Note that, even though we are referring to Hi(.) as covariate history, it actually includes
the baseline covariates as well as the random effects through the conditional mean of the
longitudinal process as described in Equation (3.3). Thus Hi(.) is not completely observable.
The time-dependent AFT model is represented by
T0 =
∫ Ti
0
exp{β′Hi(s, bi)}ds, (2.3)
with T0 = exp() as defined before. Therefore, the hazard function conditional on H¯i(t, bi)
can be expressed by
λ(t|H¯i(t, bi)) = λ0
(∫ t
0
exp{β′Hi(s, bi)}ds
)
exp{β′Hi(t, bi)}, (2.4)
where λ0 is the hazard function of T0, and is usually referred to as baseline hazard function.
In this paper, we focus on the case when the explicit form of λ0 is known. In other
words, the distribution of error term  is known. As indicated in Models (2.3) and (2.4), the
entire history of the longitudinal process influences the hazard for subject i at time t, while
in the time-dependent Cox model, the hazard function depends on the covariate history only
through the current covariate value.
2.3 INFERENCE PROCEDURE UNDER A CASE-COHORT DESIGN
Under a case-cohort design, the longitudinal information of controls outside the subcohort
are missing by design. It is natural to apply the statistical methods for missing data problem
to case-cohort data. Adopting the framework presented by Zeng et al. (2006) [60] and Tseng
and Liu (2009) [51], we assume that the longitudinal data is missing at random (MAR) and
noninformative (Little and Rubin, 2002) [33], because the probability of missing only depends
on the observed event histories and usually some baseline covariates under case-cohort design.
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We further assume that the measurement schedule ti is independent of baseline covariates
Xi, future longitudinal measurements, and random effects bi. Therefore the statistical infer-
ence can be based on the observed data. To handle the censored biomarker measurements
due to LODs, we use the method similar to Lyles et al.(2000) [36]. The likelihood function
is constructed using the conditional density function fw(Wij|bi) for observed measurements
and the cumulative distribution function Fw(τl|bi) or 1−Fw(τu|bi) for censored observations.
The observed data likelihood function for parameters of interest, φ = (β, η,Σ, σ2)′, can then
be written as
L(φ, λ0) =
n∏
i=1
li(φ, λ0) (2.5)
where
li(φ, λ0) =

∫ {∏mi
j=1 fw(Wij|bi)I(dij=0)Fw(τl|bi)I(dij=1)(1− Fw(τu|bi))I(dij=2)
}
×f(Yi,∆i|bi)fb(bi)dbi if Ri = 1∫
f(Yi,∆i|bi)fb(bi)dbi if Ri = 0
,
(2.6)
f(Yi,∆i|bi) and fb(bi) respectively define the likelihood contribution from the survival com-
ponent, and the marginal density of the random effect bi. For our study, we considered the
following specific models:
fw(w|bi) = (2piσ2)− 12 exp
{
− [w − Z(tij, bi)]
2
2σ2
}
,
f(y, δ|bi) =
[
λ0
(∫ y
0
exp{β′H(s, bi)}ds
)
exp{β′H(y, bi)}
]δ
× exp
{
−
∫ ∫ y
0 exp{β′H(s,bi)}ds
0
λ0(u)du
}
, (2.7)
fb(b) = (2pi)
− p
2 |Σ|− 12 exp{−b′Σ−1b/2},
where p is the dimension of random effect bi. Note that, for simplicity, we have dropped
the fixed parameters from the density notation. Traditional case-cohort analysis uses the
data from case cohort members only, here we also incorporate the information of event
time and any available covariate information for the controls outside the subcohort (Ri =
0). With fully specified baseline hazard function λ0, we have a parametric form of an
9
accelerated failure time model. Liu and Huang (2008) [34] suggested the use of Gaussian
quadrature for estimation of proportional hazards models including fraity terms. We adopt
this estimation method and apply the Gaussian quadrature technique to approximate the
integrals in Equation (2.5) by weighted sums over predefined abscissas for the random effects.
We set the number of abscissas as five because numerical studies have shown that Gaus-
sian quadrature with five quadrature points provides a good approximation to the true
likelihood function, and the logarithm of L˜(φ, λ0) can be maximized by the quasi-Newton
method (Liu and Huang, 2008 [34]).
The implementation of this approach is straightforward using Proc NLMIXED procedure
of SAS 9.3, because no term is left unspecified in the likelihood function and the random
effects are assumed to follow a multivariate normal distribution. However, similar to many
other non-linear models, the choice of initial values is critical in terms of the accuracy of
the final estimate and the computational time. We apply a two-stage approach to acquire
initial values: first, we model longitudinal data with a mixed effects model; then we use
the resulting estimates as if they were observed to obtain the estimates for the AFT model
based on the likelihood function in (2.7). The estimates from two-stage analysis are used
as the initial values for the estimation algorithm. Our estimators are expected to retain all
the advantageous asymptotic properties of maximum likelihood estimator (MLE), such as
consistency, efficiency and asymptotic normality under certain regularity conditions. The
corresponding standard errors can be directly obtained from the inverse, or generalized
inverse if singular, of negative Hessian matrix. Therefore, formal inference, e.g. confidence
intervals and tests of hypothesis, can be conducted via the Wald method.
2.4 SIMULATION STUDIES
We carry out a number of simulation studies to investigate the performance of the proposed
estimation procedure and assess the efficiency of the case-cohort design compared to the full
cohort design. We generate longitudinal and survival data from three joint models as follows.
The first joint model (M1) consists of: (i) a mixed effects model with only random
10
intercept:
Wij = l0 + l1tij + b0i + ij, (2.8)
where the fixed intercept and slope, (l0, l1), represent the overall trend of longitudinal mea-
surements over time; the random intercept, b0i ∼ N (0, σ20), reflect the heterogeneity among
subjects; and the random errors, ij ∼ N (0, σ2) represent the variation within subject and
are independent of random effects; (ii) an AFT model, assuming the survival time is related
to the longitudinal measurements through the random intercept only:
T0 = Ti exp{βb0i + ηXi}, (2.9)
where T0 follows a weibull distribution with a shape parameter a and a scale parameter b.
The second joint model (M2) consists of: (i) the same mixed effects model as describled
in M1; (ii) an AFT model, assuming the survival time is related to the true underlying
longitudinal process:
T0 =
∫ Ti
0
exp{β(l0 + l1s+ b0i) + ηXi}ds, (2.10)
where T0 follows an exponential distribution with hazard rate λ0 and Xi is a vector of baseline
covariates that affects the survival time. The third joint model (M3) consists of: (i) a mixed
effects model with both random intercept and slope:
Wij = l0 + l1tij + b0i + b1itij + ij, (2.11)
where l0, l1, b0i and ij are the same as describled in M1, random slope b1i ∼ N (0, σ21) and
is independent of b0i; (ii) an AFT model given by
T0 =
∫ Ti
0
exp{β(l0 + l1s+ b0i + b1is) + ηXi}ds, (2.12)
where T0 follows an exponential distribution with hazard rate λ0. Ten measurements are
preliminarily scheduled for each subject i at ti = (1, 2, ..., 10), and no measurement is avail-
able after the occurrence of the event of interest or censoring. The baseline covariate Xi
is drawn from a binomial distribution with probability 0.5. To allow for various degrees of
association between the longitudinal process and event time, we set β to be 0.1 and 0.5.
The other parameters are specified as: a = 2, b = 2, l0 = 1, l1 = 2, η = 1, σ
2
0 = 1, and
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σ2 = 1 for M1; λ0 = 0.002, l0 = 0.5, l1 = 10, η = 1, σ
2
0 = 0.5, and σ
2 = 1 for M2; and
λ0 = 0.002, l0 = 0.5, l1 = 10, η = 1, σ
2
0 = 0.25, σ
2
1 = 0.25, and σ
2 = 1 for M3.
The censoring time, Ci, is generated from exponential distributions with hazard rates
chosen appropriately such that the resulting proportions of cases are expected to be about
20% or 10%. We generate 500 full cohort data sets under each simulation with sample
sizes of N=600 and 1200. For each data set, we empirically choose detection limits to
achieve 10%, 20%, and 40% censoring rates for the longitudinal measurements. We select
subcohorts by two different sampling proportions such that the ratios of cases to controls
in the resulting case-cohort studies are 1:1 and 1:2, respectively. We obtain the maximum
likelihood estimators and their standard errors by the method proposed in section 3.
Tables 2.4, 2.4, and 2.4 summarize the performance of the proposed estimators for β,
which is of our primary parameter of interest, under three models, M1, M2 and M3, respec-
tively. The results for 20% censoring rate due to detection limits were similar and hence
are not presented here. As indicated in the simulation results, the proposed estimators are
approximately unbiased in all cases. The biases of the proposed estimators are all minimal.
Furthermore, the means of the estimated standard errors are in good agreement with the
empirical standard deviations of the estimates. The coverage rates of 95% confidence in-
tervals match the nominal level. We compute the relative efficiency (RE) of βˆ as the ratio
of mean square errors (MSE) of the full cohort estimator to the case-cohort estimator. As
shown in Table 1, for β = 0.5, under 10% failure rate, the case-cohort estimate of β retains
about 70% efficiency of the full cohort estimate when longitudinal covariate information is
obtained from only 20% (1:1 case-to-control ratio) of the full cohort subjects. When the
effect of longitudinal covariate is weaker (β = 0.1), the loss of efficiency becomes larger,
however at least 60% efficiency is achieved with 30% of the full cohort subjects. As ex-
pected, the efficiency of the case-cohort estimator increases with case-cohort sample size and
failure rate. Our method still performs well when the censoring proportion of longitudinal
covariate measurements is as high as 40%. Similar results are seen in Tables 2.4 and 2.4 for
the cases where the survival time is related to the longitudinal covariate through the entire
covariate process rather than just the random intercept as in M1.
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The biases of the proposed estimators for other parameters in Models (2.9), (2.10) and
(2.12) are relatively small (results not presented). The standard deviations of the case-cohort
estimates for η are almost the same as full-cohort estimates, indicating that for the covariate
that is available for every subject, our case-cohort estimator is as efficient as the full-cohort
estimator. Comparing to full-cohort estimates, the efficiency loss is small for the case-cohort
estimates of the parameters that specify the baseline survival function. But the case cohort
estimates for the regression parameters in the mixed effects model show relatively larger
efficiency loss.
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Table 1: Simulation results for β under model M1 where T0 follows a Weibull distribution with 500 replications.
Pc β N Design
20% cases 10% cases
Bias(βˆ) MeanSE SD(βˆ) 95%CP RE Bias(βˆ) MeanSE SD(βˆ) 95%CP RE
0.1
0.1
600
Full cohort 0.001 0.048 0.048 0.948 — 0.004 0.073 0.080 0.932 —
CC 1:2 0.001 0.053 0.055 0.936 0.822 0.008 0.092 0.099 0.932 0.635
CC 1:1 0.002 0.058 0.059 0.940 0.684 0.003 0.101 0.110 0.924 0.522
1200
Full cohort 0.004 0.034 0.035 0.946 — 0.003 0.051 0.051 0.952 —
CC 1:2 0.003 0.038 0.039 0.932 0.824 0.001 0.063 0.063 0.950 0.649
CC 1:1 0.004 0.041 0.042 0.944 0.691 0.001 0.070 0.074 0.940 0.526
0.5
600
Full cohort 0.002 0.058 0.057 0.956 — 0.003 0.077 0.081 0.952 —
CC 1:2 0.002 0.062 0.063 0.944 0.878 <0.001 0.088 0.090 0.946 0.779
CC 1:1 0.003 0.065 0.066 0.948 0.801 0.001 0.093 0.097 0.938 0.697
1200
Full cohort <0.001 0.041 0.039 0.952 — 0.002 0.055 0.055 0.946 —
CC 1:2 <0.001 0.043 0.042 0.962 0.883 0.004 0.062 0.065 0.952 0.786
CC 1:1 <0.001 0.045 0.044 0.960 0.806 0.005 0.065 0.066 0.942 0.711
0.4
0.1
600
Full cohort 0.001 0.049 0.049 0.952 — 0.005 0.075 0.082 0.928 —
CC 1:2 0.001 0.054 0.056 0.934 0.823 0.009 0.094 0.102 0.936 0.633
CC 1:1 0.003 0.059 0.061 0.942 0.682 0.003 0.103 0.114 0.918 0.525
1200
Full cohort 0.003 0.035 0.036 0.942 — 0.002 0.052 0.052 0.952 —
CC 1:2 0.003 0.038 0.040 0.946 0.819 0.001 0.064 0.065 0.948 0.650
CC 1:1 0.004 0.042 0.043 0.948 0.685 <0.001 0.071 0.076 0.946 0.525
0.5
600
Full cohort 0.001 0.061 0.059 0.952 — 0.004 0.082 0.083 0.956 —
CC 1:2 0.002 0.066 0.066 0.948 0.862 0.001 0.094 0.094 0.952 0.756
CC 1:1 0.004 0.070 0.070 0.950 0.769 0.001 0.100 0.102 0.944 0.662
1200
Full cohort 0.001 0.043 0.042 0.958 — 0.002 0.058 0.059 0.948 —
CC 1:2 <0.001 0.046 0.045 0.962 0.868 0.005 0.066 0.070 0.954 0.763
CC 1:1 <0.001 0.049 0.048 0.964 0.777 0.005 0.070 0.072 0.954 0.676
a = 2, b = 2, l0 = 1, l1 = 2, η = 1, σ
2
0 = 1, σ
2 = 1. Pc refers to proportion of longitudinal measurements censored due
to detection limit. CC 1:2 and CC 1:1 refer to case-cohort study with case-to-control ratio as 1:2 and 1:1, respec-
tively. RE refers to the relative efficiency of case-cohort estimator, defined by the ratio of mean square errors(MSE)
with the full cohort design as a reference.
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Table 2: Simulation results for β under model M2 where T0 follows an Exponential distribution with 500
replications.
Pc β N Design
20% cases 10% cases
Bias(βˆ) MeanSE SD(βˆ) 95%CP RE Bias(βˆ) MeanSE SD(βˆ) 95%CP RE
0.1
0.1
600
Full cohort 0.001 0.008 0.008 0.954 — 0.002 0.010 0.011 0.948 —
CC 1:2 0.002 0.009 0.009 0.958 0.781 0.003 0.013 0.014 0.954 0.620
CC 1:1 0.002 0.010 0.011 0.946 0.636 0.003 0.015 0.015 0.964 0.491
1200
Full cohort 0.001 0.006 0.006 0.942 — 0.001 0.007 0.007 0.944 —
CC 1:2 <0.001 0.006 0.006 0.952 0.801 0.002 0.009 0.009 0.960 0.630
CC 1:1 0.001 0.007 0.007 0.958 0.644 0.002 0.010 0.010 0.954 0.508
0.5
600
Full cohort 0.007 0.040 0.040 0.944 — 0.013 0.048 0.047 0.960 —
CC 1:2 0.007 0.045 0.046 0.950 0.813 0.016 0.061 0.057 0.980 0.634
CC 1:1 0.009 0.050 0.049 0.964 0.650 0.016 0.068 0.067 0.966 0.514
1200
Full cohort 0.002 0.028 0.027 0.948 — 0.007 0.034 0.034 0.960 —
CC 1:2 0.002 0.031 0.030 0.950 0.809 0.010 0.042 0.043 0.960 0.614
CC 1:1 0.004 0.035 0.034 0.950 0.644 0.010 0.047 0.047 0.954 0.505
0.4
0.1
600
Full cohort 0.001 0.008 0.008 0.960 — 0.002 0.011 0.011 0.956 —
CC 1:2 0.002 0.010 0.010 0.956 0.764 0.003 0.014 0.015 0.956 0.587
CC 1:1 0.002 0.011 0.011 0.940 0.611 0.004 0.016 0.016 0.968 0.462
1200
Full cohort 0.001 0.006 0.006 0.952 — 0.001 0.007 0.008 0.942 —
CC 1:2 <0.001 0.007 0.007 0.960 0.783 0.002 0.010 0.010 0.956 0.598
CC 1:1 0.001 0.008 0.007 0.970 0.622 0.002 0.011 0.011 0.956 0.478
0.5
600
Full cohort 0.007 0.041 0.041 0.952 — 0.013 0.049 0.049 0.962 —
CC 1:2 0.006 0.046 0.048 0.944 0.807 0.016 0.064 0.061 0.962 0.609
CC 1:1 0.008 0.052 0.050 0.966 0.632 0.017 0.072 0.073 0.976 0.479
1200
Full cohort 0.002 0.029 0.028 0.962 — 0.007 0.034 0.034 0.960 —
CC 1:2 0.003 0.032 0.032 0.960 0.796 0.011 0.044 0.045 0.950 0.592
CC 1:1 0.005 0.037 0.036 0.954 0.619 0.010 0.050 0.049 0.958 0.479
λ0 = 0.002, l0 = 0.5, l1 = 10, η = 1, σ
2
0 = 0.5, σ
2 = 1. Pc refers to proportion of longitudinal measurements censored
due to detection limit. CC 1:2 and CC 1:1 refer to case-cohort study with case-to-control ratio as 1:2 and 1:1, respec-
tively. RE refers to the relative efficiency of case-cohort estimator, defined by the ratio of mean square errors(MSE)
with the full cohort design as a reference.
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Table 3: Simulation results for β under model M3 where T0 follows Exponential distribution with 500 replica-
tions.
Pc β N Design
20% cases 10% cases
Bias(βˆ) MeanSE SD(βˆ) 95%CP RE Bias(βˆ) MeanSE SD(βˆ) 95%CP RE
0.1
0.1
600
Full cohort 0.001 0.007 0.007 0.950 — 0.002 0.009 0.009 0.956 —
CC 1:2 0.001 0.008 0.008 0.952 0.790 0.003 0.010 0.010 0.960 0.670
CC 1:1 0.001 0.009 0.008 0.946 0.679 0.004 0.012 0.011 0.954 0.502
1200
Full cohort <0.001 0.005 0.005 0.958 — 0.001 0.006 0.006 0.948 —
CC 1:2 <0.001 0.005 0.005 0.954 0.800 0.001 0.007 0.007 0.948 0.675
CC 1:1 <0.001 0.006 0.005 0.956 0.687 0.002 0.008 0.008 0.946 0.561
0.5
600
Full cohort 0.008 0.056 0.056 0.958 — 0.015 0.060 0.060 0.956 —
CC 1:2 0.008 0.060 0.060 0.954 0.864 0.020 0.072 0.071 0.948 0.682
CC 1:1 0.009 0.065 0.065 0.946 0.735 0.022 0.077 0.077 0.954 0.589
1200
Full cohort 0.009 0.042 0.042 0.948 — 0.009 0.045 0.045 0.946 —
CC 1:2 0.010 0.047 0.046 0.950 0.812 0.010 0.054 0.055 0.950 0.684
CC 1:1 0.010 0.049 0.049 0.946 0.722 0.011 0.059 0.060 0.946 0.579
0.4
0.1
600
Full cohort 0.001 0.007 0.007 0.954 — 0.002 0.009 0.009 0.954 —
CC 1:2 0.001 0.008 0.008 0.956 0.772 0.002 0.011 0.012 0.956 0.614
CC 1:1 0.001 0.009 0.010 0.956 0.609 0.002 0.013 0.012 0.956 0.490
1200
Full cohort <0.001 0.005 0.005 0.954 — 0.001 0.006 0.006 0.950 —
CC 1:2 <0.001 0.005 0.005 0.954 0.795 0.001 0.008 0.008 0.956 0.626
CC 1:1 <0.001 0.006 0.005 0.955 0.667 0.001 0.009 0.010 0.958 0.502
0.5
600
Full cohort 0.008 0.052 0.053 0.974 — 0.018 0.062 0.063 0.963 —
CC 1:2 0.009 0.056 0.056 0.974 0.860 0.024 0.078 0.079 0.954 0.643
CC 1:1 0.009 0.061 0.060 0.968 0.728 0.027 0.085 0.085 0.959 0.530
1200
Full cohort 0.007 0.040 0.041 0.950 — 0.010 0.042 0.043 0.967 —
CC 1:2 0.008 0.045 0.046 0.948 0.789 0.014 0.050 0.048 0.967 0.666
CC 1:1 0.008 0.048 0.048 0.946 0.696 0.018 0.056 0.054 0.961 0.534
λ0 = 0.002, l0 = 0.5, l1 = 10, η = 1, σ
2
0 = 0.25, σ
2
1 = 0.25, σ
2 = 1. Pc refers to proportion of longitudinal measure-
ments censored due to detection limit. CC 1:2 and CC 1:1 refer to case-cohort study with case-to-control ratio as
1:2 and 1:1, respectively. RE refers to the relative efficiency of case-cohort estimator, defined by the ratio of mean
square errors(MSE) with the full cohort design as a reference.
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2.5 APPLICATION
We illustrate the proposed estimation procedure with the cytokine data of the Genetic and
Inflammatory Markers of Sepsis (GenIMS) study. GenIMS is a multi-center cohort study
that enrolled 2320 subjects from the emergency department (ED) with community acquired
pneumonia (CAP) in 28 US academic and community hospitals between 2001 and 2003
(Kellum et al. 2007 [25]). One of the primary goals is to identify important inflammatory
markers that indicate the risk of severe sepsis and subsequent adverse outcomes, e.g. 90-day
mortality. Cytokines including tumor necrosis factors, interleukin-6 (IL6) and interleukin-
10 (IL10), were measured for patients admitted to the hospital daily during the first week,
and weekly thereafter while they were still in the hospital. We consider IL6 as an example
to demonstrate the proposed method, and the objective of our analysis is to investigate
whether IL6 changed over time in the first week of hospitalization and how IL6 trajectory
was associated with the 90-day mortality.
Among 1895 patients who were confirmed CAP cases admitted to hospitals, 1707 patients
had at least one IL6 measurement. All measurements were transformed into a natural log
scale to normalize the distribution. The IL6 has two lower detection limits at 2 pg/ml and 5
pg/ml. Censoring proportions from day 1 to day 7 were 14.6%, 21.6%, 29.3%, 32.6%, 34.1%,
35.4%, and 34.4%, respectively. For our analysis, we defined cases as subjects died within 90
days from enrollment. Figure 1 presents the boxplots of log transformed IL6 levels in the first
week of hospitalization by 90-day survival status. Overall IL6 concentration was decreased
over time for both survivors and nonsurvivors, and nonsurvivors seemed to have higher IL6
at earlier days. The availability of the full cohort data on IL6 allows us to compare the
proposed case-cohort estimators to the full cohort estimators. There are about 10% cases
among the full cohort. We select subcohorts by different sampling proportions such that the
resulting case-cohort studies have 1:1 and 1:2 case-to-control ratios, respectively.
In order to identify an appropriate model for GenIMS data, we consider several joint
models for the longitudinal IL6 data and survival data: 2 linear mixed effects models for
the natural log transformed IL6, one with random intercept only and the other with both
random intercept and slope, 4 AFT models adjusted for baseline characteristics (gender, race
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and ICU use) with baseline survival time T0 following exponential, Weibull, loglogistic, and
lognormal distributions, respectively. We fit linear mixed effects models and survival models
seperately to abtain the initial values of parameter estimates. We compare model fitting
under a joint modelling framework using Akaike information criterions (AICs) and Bayesian
information criterions (BICs). The linear mixed effects model with both random intercept
and slope fail to provide positive-definite Hessian matrixes in the joint analysis, thus this
model is dropped from consideration. The AFT model adjusted for gender, race, and ICU
use and with baseline survival time following a Weibull distribution shows superiority in
both AIC and BIC (Table 4). Therefore our final joint model is
log(IL6)ij = l0 + l1tij + b0i + eij, (2.13)
T0 =
∫ Ti
0
exp{β(l0 + l1s+ b0i) + ηrracei + ηggenderi + ηicuicui}ds, (2.14)
where ti = (ti1, ti2, ..., ti7) = (1, 2, ..., 7) and T0 follows a Weibull distribution.
The results of the analysis, presented in Table 5, are consistent with what we observe
from the simulation studies, namely (1) the point estimates under case-cohort designs are
close to the full cohort estimates; and (2) the full cohort analysis and case-cohort analysis
yield almost identical standard errors for the parameter estimates of the AFT model, while
standard errors for the parameter estimates of the mixed effects model are much larger in the
case-cohort analysis, especially when the case-cohort sample size is small. In both full cohort
and case-cohort analyses, βˆ’s are all positive and lˆ1’s are negative, which indicates that the
survival time significantly decreases with increasing IL6; and IL6 level slightly decreases
over time during the first week of hospitalization. These results are consistent with what we
observed in Figure 1.
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Table 4: Akaike information criterion (AIC) and Bayesian information criterion (BIC) values
for joint analysis of a linear mixed effects model with random intercept and an AFT model
adjusted for gender, race and ICU use.
Distribution of baseline survival time (T0) AIC BIC
Exponential 27560 27600
Weibull 27289 27335
Loglogistic 27350 27395
Lognormal 27460 27482
Table 5: Joint analysis of log transformed cytokine IL6 trajectory vs 90-day mortality
adjusting for gender, race and ICU use in GenIMS study
Full cohort Case-cohort (1:2 ratio) Case-cohort (1:1 ratio)
Par Estimate SE P value Estimate SE P value Estimate SE P value
Accelerated Failure Time Model
β 0.091 0.004 <0.001 0.105 0.005 <0.001 0.112 0.006 <0.001
ηgender -0.003 0.045 0.951 -0.005 0.046 0.917 -0.005 0.046 0.908
ηrace -0.014 0.071 0.838 -0.019 0.071 0.794 -0.022 0.072 0.763
ηicu 0.053 0.048 0.269 0.059 0.048 0.219 0.063 0.049 0.195
Mixed effects Model
l0 3.685 0.041 <0.001 3.775 0.076 <0.001 3.854 0.096 <0.001
l1 -0.364 0.008 <0.001 -0.309 0.013 <0.001 -0.290 0.015 <0.001
σ20 1.460 0.029 <0.001 1.531 0.053 <0.001 1.632 0.070 <0.001
σ2 1.072 0.011 <0.001 1.095 0.020 <0.001 1.128 0.024 <0.001
gender= 1 if male, 0 otherwise; race= 1 if white, 0 otherwise; icu= 1 if yes, 0 otherwise.
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Figure 1: Boxplots for log transformed IL-6 by survival and mortality groups
2.6 DISCUSSION
The case-cohort design is a cost-effective approach to collect data for large cohort studies
when exposure variables such as biomarkers or genetic markers are expensive to measure for
every subject. We have proposed a modified likelihood-based method for case-cohort designs
when accelerated failure time models are used to assess the effect of longitudinal covariate
that are subject to measurement error and detection limits. All the event data and easily
measured covariates are taken into account in our estimation procedure while classical case-
cohort analysis only uses information from the case-cohort sample. We considered a simple
case-cohort design where the subcohort is selected by a simple random sampling. A stratified
case-cohort design is usually more efficient when the stratification variables are correlated
with the outcome of interest. It is straightforward to account for the effect of stratification
variables in the AFT model by using stratum specific baseline hazard functions.
When the baseline hazard function in the accelerated failure time model is left unspeci-
fied, it becomes challenging to obtain the MLEs. Unlike the Cox model, the baseline hazard
function of an AFT model involves both random effects and unknown parameters, which
prohibits the use of both the direct maximum likelihood estimation and the nonparamet-
ric maximum likelihood estimation with a discrete mass function. Tseng, et. al. (2005)
suggested use of a piece-wise constant step function to approximate the baseline hazard
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function and presented a Monte Carlo expectation-maximization (EM) algorithm (Demp-
ster, Laird, and Rubin, 1977) to obtain the estimates. Although their estimation procedure
performed well as indicated in the simulation studies, it is highly intensive in programming
and computation.
With a fully specified baseline hazard function, our method can be easily implemented in
SAS Proc NLMIXED procedure and is applicable to nested case-control designs. As demon-
strated in the simulation study, the efficiency loss of the proposed case-cohort estimators are
relatively small for parameters in the AFT model comparing to full-cohort estimators. In
addition, our estimators are almost as efficient as the full-cohort estimators for the covari-
ates that are observed for each individual in the full cohort. However, the efficiency loss can
be large for these parameters in the longitudinal model, because information of an survival
outcome and baseline covariates are available for every subject in the cohort while longitu-
dinal information is only available for subjects in the case-cohort sample. When a battery
of markers is selected from different biological pathways for studying a complex disease, a
case-cohort design can be used as an efficient method for initial identification of markers
associated with the clinical outcomes while preserving blood samples and reducing the cost.
Interesting extensions of this work include the development of a similar joint-model
framework to capture the dependencies between multivariate longitudinal data and time-to-
event data, the use of generalized estimation equation method in the estimation procedure,
and the control for misclassification error when the longitudinal data is categorical.
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3.0 INFERENCE FOR MEAN QUALITY ADJUSTED LIFETIME WITH
QUALITY OF LIFE MEASURED REPEATEDLY WITH ERROR
3.1 INTRODUCTION
Survival time is one of the most definitive endpoints used in clinical trials to evaluate the
effectiveness of alternative treatments. It is powerful in revealing biological differences in
treatment effects, but may be inadequate for deciding the actual benefits for patients. Other
end points, such as progression-free survival, physical and psychological health status, and
duration of response, are also commonly used for making decisions about medical treatments
and the settings of health care programs. Separate analyses of these end points are valid for
comparing different aspects of treatments. The choice is straightforward when one treatment
shows superiority in all relevant end points. However, the conclusion is difficult to draw when
different end points favor different treatments. For instance, a therapy with longer survival
time may cause more pain and loss of physical capacity. In this case, the medical decision
should be made after evaluating tradeoffs between health benefits and undesirable side effects,
in other words, quality of life and length of life. Gelber, Gelman and Goldhirsch (1989)
[14] addressed this issue by introducing a quality-of-life-oriented endpoint, time without
symptoms of disease and toxicity (TWiST). TWiST is defined by subtracting time with toxic
effect of therapy and time with unpleasant symptoms of disease from the overall survival
time. It presents the good quality time enjoyed by patients while on treatment.
The concept of quality-adjusted lifetime (QAL) introduced by Goldhirsch et al. (1989)
[18] has been considered as an objective measurement that summarizes the quantitative and
qualitative health aspects in a unitary and meaningful way. Since its introduction QAL
has occupied a significant area of clinical and biomedical research in treatment comparisons,
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especially for chronic diseases such as cancer,cardiovascular diseases, and AIDS. The idea is
to divide each patient’s health experience into several intermediate states, with death at one
extreme and perfect health at the other extreme. The time spent in each state is weighted by
a utility coefficient ranging from zero to one. The value of the coefficient is decided according
to subjective judgments of the quality of life (QOL) that state renders. The perfect healthy
state has value one while the absorbing state equivalent to death has value zero. This leads
to a utility function over time which takes the value of the utility coefficient of the state
occupied at that time. QAL is defined as an integration of this utility function over the
survival duration.
In almost all previous works, the health states were defined to be discrete and the number
of states were taken to be finite. For discrete, finite states, QAL can be calculated as a sum
of time spent at each health state multiplied by the corresponding weight and considered as
equivalent to time with perfect health. Gelber, Goldhirsch, and Cavalli (1991) [15] defined
QAL by considering three health states: time without symptoms and toxicity (TWiST), time
with toxicity (TOX), and survival time after relapse (REL). TWiST is weighted as one and
naturally the other two are weighted less. Korn (1993) [29] considered a biased estimator for
the distribution of an interpolated area under QOL curve accounting for informative censor-
ing. Zhao and Tsiatis (1997) [62] proposed an estimator of the QAL distribution along with
a consistent estimator of its asymptotic variance when the survival time is subject to right
censoring. van der Laan and Hubbard (1999) [53] extended this work to incorporate addi-
tional time-dependent and time-independent covariates. They showed that their estimator
is locally efficient even with dependent censoring. Pradhan and Dewanji (2009) [39] derived
a parametric estimator of the QAL distribution for the progressive illness-death models.
In addition to literature developing methods for estimating the distribution of QAL, the
mean of QAL has also been studied by many researchers and considered as an important
parameter of interest in treatment comparisons. Cole et al. (1993) [8] considered a Cox
type parametric regression model to estimate mean QAL using the bootstrap method to
obtain the variance estimate. Hwang, Tsauo and Wang (1996) [24] suggested an estimator
for the expected quality adjusted survival with quality of life information collected from a
cross-sectional survey. Huang and Louis (1999) [23] presented a nonparametric estimation of
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the expected quality-adjusted survival time for a general multistate process with incomplete
follow-up data. Zhao and Tsiatis (2000) [63] derived a class of consistent and asymptotically
normal estimators of mean QAL with right censored data in a more general setting. Wang
and Zhao (2007) [57] developed a regression method to investigate the covariate effects on
the mean QAL with right-censored data. Andrei and Murray (2007) [2] proposed regression
models for the mean of the quality-of-life-adjused restricted survival time using pseudo-
observations. Zhao and Wang (2008) [64] considered the empirical likelihood method for the
regression model of mean QAL with right-censored data.
In all previous studies the quality function is assumed to be a step function, taking
constant value at various states. In most applications, QOL is measured using continuous
scales, with scores ranging over some specified intervals. Over the past two decades, several
QOL scales have been developed and widely used to describe the change of patients’ health
status continuously for different diseases. For example, the European Organization for Re-
search and Treatment of Cancer (EORTC) provided QOL scales for use in international
clinical trials in oncology [1]. A QOL scale for gastroesophageal reflux disease (GERD) was
developed and found to be a valid, reliable, practical, and responsive measure of QOL for
patients with GERD by Velanovich et al. (1996) [54]. A reasonable approach to estimate
QAL would then be to utilize their QOL measurements in the definition of QAL. Usually
the QOL scores are collected repeatedly with error during the course of treatment or the
study period. Thus a linear mixed effects model can be applied to describle the trajectory of
quality of life scores, which represents the continuous health experience of each patient. We
define quality-adjusted lifetime as the survival time adjusted for the continually changing
health status through a link function that maps the quality-of-life scores to the interval [0,1].
To improve the estimation of parameters in the linear mixed effects model, we apply joint
modelling method to longitudinal quality-of-life scores and the survival time.
It is well known that the Kaplan-Meier estimator for the survival distribution of QAL is
biased due to the induced informative censoring (Gelber, et al., 1989 [14]). To eliminate this
bias, Glasziou et al. (1990) [17] propose a consistent estimator for mean QAL for progressive
state models, in which patients’ health state changes from one to another following a fixed
sequence. Their estimator of mean QAL is calculated as the weighted sum of areas under the
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separate Kaplan-Meier survival curves for each health state, but no consistent estimator for
the variance is provided. Furthermore, right censoring is very common in clinical trials due
to the lost to follow-ups and the restriction on the length of studies. Therefore, the complete
health experience, as well as the survival time, cannot be observed for all patients. With
censored data, a consistent nonparametric estimate of mean QAL over the entire health
history cannot be obtained. Zhao and Tsiatis (2000) [63] suggest calculating mean QAL
restricted to a certain length of time, which is usually determined by the length of study, and
applying the general representation theorem for the missing data process developed by Robins
and Rotnitzky (1992) [41] and Robins, et al. (1994) [42] to derive a class of consistent and
asymptotically normal estimators for mean QAL and their asymptotic variance in a general
setting. We borrow the basic idea from them and derive a consistent and asymptotically
normal estimator for mean QAL and its asymptotic variance where the utility function is
esimated from the data based on the QOL scores.
In Section 3.2 and 3.3 we introduce the notation and estimation of mean QAL with its
asymptotic variance. Section 3.4 describles the simulation studies we conducted to evaluate
our estimators. Section 3.5 provides some discussions and possible direction of future works.
3.2 METHOD
3.2.1 Set-up
To begin, we introduce some notation and the data structure. For the ith individual, let
T ∗i be the potential event time, such as time to death, time to disease progression or time
to infection, and Ci be the potential right censoring time, such as time to lost to follow-up
or time to the end of the study, respectively. Due to the presence of censoring, we have to
consider quality adjusted lifetime within a restricted length of time. Let L denote a time after
which a reasonable proportion of individuals are still being followed. L is usually determined
by the length of study. Therefore, the survival time would be defined as Ti = min(T
∗
i , L).
We define QAL for the ith patient as
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Ui =
∫ Ti
0
Q(Wi(t))dt, (3.1)
where Q is a monotone link function that maps the QOL process W (.) to the interval [0, 1],
where 0 indicates the lowest quality of life such as death and 1 indicates the best quality,
e.g. perfect health. The function Q is usually known and parameterized, for example, using
an inverse logit function. Thus Q(Wi(t)) for an inverse logit link can be written as
Q(Wi(t)) =
 0 if t > Tilogit−1{qWi(t)} if t ≤ Ti , (3.2)
where the scale parameter q changes the scale of the QOL scores in the QAL function.
3.2.2 Observed Data
Due to right censoring survival times are not always observed completely. Denote the ob-
served event time and event indicator as Yi and 4i, respectively, where Yi = min(Ti, Ci)
and 4i = 1, if Ti ≤ Ci, and 0 otherwise. QOL scores are measured usually at fixed time
points until the terminal event. Assume the quality of life scores Wi = {Wi1,Wi2, . . . ,Wimi}
are obtained from the ith individual at time ti = {ti1, ti2, . . . , timi}, for timi ≤ Ti. Let
Xi(t) and Zi(t) be possible time-dependent covariate vector process that are potentially
associated with mean and subject-specific QOL score and Vi be a baseline covariate vec-
tor. Then the observed data for the ith individual is {Yi,4i, Xi, Zi, Vi,Wi, ti}, where Xi =
{Xi1, Xi2, . . . , Ximi} and Zi = {Zi1, Zi2, . . . , Zimi} are the realizations of Xi(t) and Zi(t),
respectively, at time ti = {ti1, ti2, . . . , timi}. Our goal is to draw inferences about the mean
QAL, µ = E(U) = E
[∫ T
0
Q(W (t))dt
]
.
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3.3 INFERENCE
3.3.1 Models
As mentioned in Section 3.2.1, we define the QAL for the ith patient as
Ui =
∫ Ti
0
Q(Wi(t))dt.
However, the QOL process Wi(t) is unknown for all t. It is measured with error only at
fixed timepoints as the QOL score Wij for the ith individual at time tij, for tij ≤ Yi.
Given the dependence between the quality of life and the occurence of a terminal event, we
propose to estimate the QOL process Wi(t) by jointly modeling the observed QOL scores
and the survival data. More specifically, we can define marginal models for the QOL scores
and the survival data with shared random effects and estimate the parameters of interest
by maximizing the joint likelihood of these two marginal models. We propose to use the
marginal models specified in Sections 3.3.1.1 and 3.3.1.2.
3.3.1.1 Model for the longitudinal QOL score We propose using a linear mixed
effects model for the observed QOL score Wij. The proposed model can be writen as
Wij = Wi(tij) +Gi(tij) + eij
= f(Xi(tij); β) + g(Zi(tij); bi) + eij, (3.3)
where Wi(t) = f(Xi(t); β) describes the trajactory of mean QOL scores modeled as a func-
tion of the fixed effect β and its design vector Xi(t) that might contain individual baseline
covariates and the measurement times tij; Gi(t) = g(Zi(t); bi) represents the within sub-
ject variation modeled as a function of the random effect bi and its subject specific design
vector Zi(t) that also might be time-dependent; and eij is the measurement error, assumed
to be independently normally distributed with mean zero and variance σ2. We assume the
random effect bi is normally distributed with mean zero and covariance matrix Σ and it is
independent of the measurement error eij. This model not only allows the assessment of
change in the QOL process over time using fixed effects, but also accounts for within subject
correlation through subject-specific random effects.
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3.3.1.2 Model for the survival time We propose using an accelerated failure time
(AFT) model to describe the survival data due to its appealing interpretation and robustness
to non-proportionality of hazards. The QOL score is closely related to the survival time
because it is defined to be a summary statistic of both the quantitative and qualitative health
aspects. We incorparate the mean QOL score as an importent covariate in the survival model
and the propose AFT model can be writen as
T0 =
∫ Ti
0
exp{αWi(s) + ηVi}ds
=
∫ Ti
0
exp{αf(Xi(s); β) + ηVi}ds, (3.4)
where T0 is referred to as the baseline survival time since it is the survival time for subjects
with all covariates equal to zero; Wi(s) = f(Xi(s); β) is a function defined the same as in
Section 3.3.1.1, where Xi(s) is a possible time-dependent design vector for fixed effect β; and
Vi is a vector of baseline covariates that affect the survival time. And the hazard function
can be expressed by
λ(t|f¯(Xi(t); β), Vi) = λ0
(
exp{ηVi}
∫ t
0
exp{αf(Xi(s); β)}ds
)
exp{αf(Xi(t); β) + ηVi},
(3.5)
where f¯(Xi(t); β) = {f(Xi(s); β), s ≤ t} is the mean QOL score trajectory up to time t, and
λ0 is the hazard function of T0 usually referred to as baseline hazard function.
3.3.1.3 Estimation of β The parameterization of the QOL process Wi(t) in terms of
fixed effect β allows us to estimate it. We obtain the maximum likelihood estimator βˆ of β
by jointly fitting Models (3.3) and (3.4) and maximizing the joint likelihood. Then, if Ti’s
were known, the QAL can be estimated as
Ui(βˆ) =
∫ Ti
0
Q(Wi(t))dt =
 0 if t > Ti∫ Ti
0
logit−1{qf(Xi(tij); βˆ)}dt if t ≤ Ti
, (3.6)
and the corresponding mean QAL could be estimated as
µˆ =
1
n
n∑
i=1
Ui(βˆ). (3.7)
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However, Ti’s are not all known, and hence the above estimator is not of practical use.
One, therefore, may choose to predict Ti based on Model (3.4) and replace the predicted
Ti in the above equation to obtain a predicted Ui, namely Uˆi(βˆ) and then average over all
subjects to construct an estimator of µ. We refer to this estimator as
µˆP =
1
n
n∑
i=1
Uˆi(βˆ). (3.8)
Prediction of survival times are often cumbersome, specially, in the presence of time-dependent
covariates. Therefore, we will use inverse-probability weighting method to account for the
censored survival times in Equation (3.6). We describe the detailed procedure and the cor-
responding large sample properties in the next section.
3.3.2 Estimation of mean QAL
Inverse probability weighting has been used extensively in the analysis of survival data. For
instance, Rotnitzky and Robins (2005) [43] discussed inverse probability weighted augmented
estimation in survival studies, which provides a robust approach to model misspecification;
and Xie and Liu (2005) [59] proposed adjusted Kaplan-Meier estimator with inverse proba-
bility of treatment weighting for survival data. Zhao and Tsiatis (2000) [63] used this in the
QAL setting to derive the estimator for mean QAL. Following their work, we propose to use
a simple weighted estimator for mean QAL:
µˆ =
1
n
n∑
i=1
4iUˆi(βˆ)
Kˆ(Yi)
, (3.9)
where Uˆi(βˆ) =
∫ Yi
0
Q(Wi(t))dt is defined the same way as Ui(βˆ) in Equation (3.6) except
that Ti is replaced by the observed Yi, and Kˆ(.) is the Kaplan-Meier estimator for the
survival distribution function of the censoring time Ci. With data {Yi = min(Ti, Ci),4i, i =
1, 2, . . . , n}, Kˆ(t) can be estimated as
Kˆ(t) =
∏
u≤t
{
1− dN
c(u)
Y (u)
}
, (3.10)
where N c(u) =
∑
i
I(Yi ≤ u,4i = 0), and Y (u) =
∑
I(Yi ≥ u). Fleming and Harrington
(1991) [13] showed that Kˆ(t) is a uniformly consistent estimator of K(t) over [0, L]. Following
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the procedure described in Section 3.3.1.3, βˆ is a consistent estimator for β, the simple
weighted estimator µˆ in Equation (3.9) for mean QAL can be shown to be a consistent
estimator, as long as that (i) given Wij, the censoring is independent of survival; (ii) the mean
model of the QOL score, E(Wij) = Wi(tij) = f(Xi(tij); β), and the AFT model described in
Section 3.3.1.2 are correctly specified. We first note that when 4i = 1, Uˆi(βˆ) = Ui(βˆ) and
Kˆ(Yi) = Kˆ(Ti), therefore, µˆ in Equation (3.9) can be written equivalently as
µˆ =
1
n
n∑
i=1
4iUi(βˆ)
Kˆ(Ti)
. (3.11)
To motivate the construction of this estimator we first show that when Kˆ(.) and βˆ are known,
i.e. Kˆ(Ti) = K(Ti), βˆ = β0. The estimator µˆ
0 = 1
n
n∑
i=1
4iUi(β0)
K(Ti)
is unbiased for µ. Specifically,
E{µˆ0} = E
{
1
n
n∑
i=1
4iUi(β0)
K(Ti)
}
=
1
n
n∑
i=1
E
[
E
{4iUi(β0)
K(Ti)
|Ti,Wi
}]
=
1
n
n∑
i=1
E
[
Ui(β0)
K(Ti)
E{I(Ci ≥ Ti)|Ti,Wi}
]
=
1
n
n∑
i=1
E
[
Ui(β0)
K(Ti)
K(Ti)
]
= E
[
1
n
n∑
i=1
Ui(β0)
]
= E[U(β0)] = E[U ] = µ. (3.12)
One then would expect that the proposed estimator µˆ defined in Equation (3.9), will be a
consistent estimator of µ, since µˆ only replaces the unknown β and K in µˆ0 by their uniformly
consistent estimators.
3.3.3 Consistency of µˆ
Since βˆ in obtained through the optimazation of the joint likelihood, βˆ is a consistent and
asymptotically normal estimator. Let
L(β) =
1
n
n∑
i=1
li(β|Yi, Xi,Wi, Vi)
where li(β|Yi, Xi,Wi, Vi) is the log joint likelihood function of Models (3.3) and (3.4). We
denote the first derivative of L(β) as L′(β) and the second derivative as L′′(β). Then by
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the definition of maximum likelihood estimate, L′(βˆ) = 0. By the Mean Value Theorem, we
know
0 = L′(βˆ) = L′(β0) + (βˆ − β0)TL′′(βˆ1),
for some βˆ1 ∈ [βˆ, β0] and L′′(βˆ1) ≈ E[L′′(β0)]. Therefore, we can write
βˆ − β0 = 1
n
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi) + op(1)
where ψi is proportional to the score equation of β0, specifically
ψi(β0|Yi, Xi,Wi, Vi) = −E[l′′(βˆ1|Yi, Xi,Wi, Vi)]−1{l′(β0|Yi, Xi,Wi, Vi)}T . (3.13)
Now Ui(βˆ) can be approximated using a Taylor’s series expansion as follow,
Ui(βˆ) ≈ Ui(β0) + (βˆ − β0)TU ′i(β0)
= Ui(β0) +
{
1
n
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi) + op(n− 12 )
}T
U ′i(β0),
where U ′i(β0) is the first derivative vector of Ui(β) with respect to β evaluated at β0. Now,
µˆ− µ = 1
n
n∑
i=1
4iUi(βˆ)
Kˆ(Ti)
≈ 1
n
n∑
i=1
4i
Kˆ(Ti)
Ui(β0) +
{
1
n
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi) + op(n− 12 )
}T
U ′i(β0)
− µ
=
1
n
n∑
i=1
4iUi(β0)
Kˆ(Ti)
− µ
+
{
1
n
n∑
i=1
4iU ′i(β0)
Kˆ(Ti)
}T
1
n
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi)
+
{
op(n
− 1
2 )
}T 1
n
n∑
i=1
4iU ′i(β0)
Kˆ(Ti)
. (3.14)
The first term in Equation (3.14) is equal to
1
n
n∑
i=1
4i{Ui(β0)− µ}
K(Ti)
− 1
n
n∑
i=1
4i{Ui(β0)− µ}Kˆ(Ti)−K(Ti)
Kˆ(Ti)K(Ti)
. (3.15)
The first term is a weighted average of n independent, identically distributed random vari-
ables, and its expected value is zero as showed in Equation (3.12). So the first term in
31
Equation (3.15) converges to zero in probability. By assumption, Ti ≤ L and K(L) > 0, the
second term is bounded from above by
supu≤L|Kˆ(u)−K(u)|
Kˆ(L)−K(L) . (3.16)
Since Kˆ(u) converges uniformly to K(u) for u ≤ L as showed by Fleming and Harrington
(Ch. 6) [13], Equation (3.16) converges to zero in probability. Therefore, the second term
converges to zero in probability. Thus Equation (3.15) converges to zero in probability. The
second term in Equation (3.14) is equal to
{
1
n
n∑
i=1
4iU ′i(β0)
K(Ti)
}T
1
n
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi)
+
{
1
n
n∑
i=1
4iU ′i(β0)
Kˆ(Ti)−K(Ti)
Kˆ(Ti)K(Ti)
}T
1
n
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi), (3.17)
where 1
n
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi) converges to zero in probability since ψi is proportional to
the score function, 1
n
n∑
i=1
4iU ′i(β0)
K(Ti)
converges to a constant vector, C, the expected value of
U ′(β0), and the second term in Equation (3.17) converges to zero in probability since it is
also bounded from above by Equation (3.16). Therefore Equation (3.17) converges to zero
in probability. Following the same logic, the third term in Equation (3.14) also converges to
zero in probability since op(n
− 1
2 ) = n−
1
2 op(1) converges to zero. This shows Equation (3.14)
converges to zero in probability. So the proposed estimator is a consistent estimator for the
mean QAL.
Furthermore, we investigate the asymptotic distribution of n
1
2 (µˆ − µ). According to
Equation (3.14), we can write
n
1
2 (µˆ− µ) = n− 12
n∑
i=1
{
4iUi(β0)
Kˆ(Ti)
− µ
}
+
{
1
n
n∑
i=1
4iU ′i(β0)
Kˆ(Ti)
}T
n−
1
2
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi)
+ {op(1)}T n−1
n∑
i=1
4iU ′i(β0)
Kˆ(Ti)
. (3.18)
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In order to find the asymptotic distribution of n
1
2 (µˆ − µ), we need to find the asymptotic
distribution of the above three terms. Let H1(β0) = n
− 1
2
{
n∑
i=1
4iUi(β0)
Kˆ(Ti)
− nµ
}
, H2(β0) =
1
n
n∑
i=1
4iU ′i(β0)
Kˆ(Ti)
and H3(β0) = n
1
2
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi). Equation (3.18) can be written as
n
1
2 (µˆ− µ) = H1(β0) + {H2(β0)}TH3(β0) + op(1)TH2(β0). (3.19)
We can rewrite H1(β0) as
H1(β0) = n
− 1
2
[
n∑
i=1
4iUi(β0)
K(Ti)
−
n∑
i=1
4iUi(β0)
{
Kˆ(Ti)−K(Ti)
Kˆ(Ti)K(Ti)
}
− nµ
]
. (3.20)
Let λc(u) be the hazard function for the censoring distribution, and the corresponding mar-
tingale process M ci (u) can be expressed as
M ci (u) = N
c
i (u)−
∫ u
0
λc(t)Y ∗i (t)dt,
where N ci (u) = I(Yi ≤ u,4i = 0) and Y ∗i (u) = I(Yi ≥ u). Let M c(u) =
∑
M ci (u),
N c(u) =
∑
N ci (u), and Y (u) =
∑
Yi(u). According to Robins and Rotnitzky (1992) [41]
that
4i
K(Ti)
= 1−
∫ ∞
0
dM ci (u)
K(u)
,
Gill (1980) [16] that
Kˆ(Ti)−K(Ti)
K(Ti)
= −
∫ Ti
0
Kˆ(u)
K(u)
dM c(u)
Y (u)
,
and
n−1Y (u) = Kˆ(u)Sˆ(u),
where Sˆ(u) is the Kaplan-Meier estimate for S(u) = pr(T > u), Equation (3.20) can be
written as
n−
1
2
n∑
i=1
{Ui(β0)− µ} − n− 12
n∑
i=1
∫ ∞
0
dM ci (u)
K(u)
{Ui(β0)− Gˆ(U, u)}, (3.21)
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where Gˆ(U, u) = 1
nSˆ(u)
n∑
i=1
4iUi(β0)I(Ti≥u)
Kˆ(Ti)
. Since Ui(β0) is F (0), the two terms in Equation
(3.21) are uncorrelated. Following the derivation in Zhao and Tsiatis (1997) [62], we rewrite
Equation (3.21) as
n−
1
2
n∑
i=1
{Ui(β0)− µ} − n− 12
n∑
i=1
∫ ∞
0
dM ci (u)
K(u)
{Ui(β0)−G(U, u)}
−n− 12
n∑
i=1
∫ ∞
0
dM ci (u)
K(u)
{G(U, u)−G∗(U, u)} − n− 12{µˆ0 − µ}
n∑
i=1
∫ ∞
0
dM ci (u)
K(u)Sˆ(u)
,(3.22)
where
G(U, u) =
1
S(u)
E{Ui(β0)I(Yi ≥ u)}
and
G∗(U, u) =
1
Sˆ(u)
{
µ− n−1
n∑
i=1
4iUi(β0)I(Ti < u)
Kˆ(Ti)
.
}
(3.23)
From the central limit theorem. the first term in Equation (3.22) is asymptotically normally
distributed with mean zero and variance V ar(Ui(β0)−µ). From the martingale central limit
theorem (Fleming and Harrington, 1991 [13]), the second term also converges to a normal
distribution with mean zero and variance
E
∫ ∞
0
[Ui(β0)−G(U(β0), u)]2I(Yi ≥ u)λ
c(u)
K(u)
du. (3.24)
According to Zhao and Tsiatis (1997) [62], the third term converges to a constant, zero, in
probability. The last term in Equation (3.22) also converges to zero since µˆ0 − µ converges
to zero in probability as shown in Equation (3.12), and
n∑
i=1
∫ ∞
0
dM ci (u)
K(u)Sˆ(u)
converges to a normal distribution by the martingale central limit theorem. Then by Slut-
sky’s theorem, H1(β0) is asymptotically normally distributed with mean zero and variance
σH1 = V ar(Ui(β0)− µ) + E
∫ ∞
0
[Ui(β0)−G(U(β0), u)]2I(Yi ≥ u)λ
c(u)
K(u)
du. (3.25)
This variance can be estimated
ˆσ2H1 = n
−1
n∑
i=1
4i{Ui(βˆ)− µˆ}2
Kˆ(Yi)
+ n−1
∫ ∞
0
dN c(u)
Kˆ(u)2
{Gˆ(U(βˆ)2, u)− Gˆ(U(βˆ), u)2}. (3.26)
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Following the same argument, H2(β0) can be written as
H2(β0) =
1
n
n∑
i=1
4iU ′i(β0)
K(Ti)
− 1
n
n∑
i=1
4iU ′i(β0)
Kˆ(Ti)−K(Ti)
Kˆ(Ti)K(Ti)
= n−1
n∑
i=1
[
dUi(β0)
dβ0
−
∫ ∞
0
dM ci (u)
K(u)
{
dUi(β0)
dβ0
− 1
S(u)
E(
dUi(β0)
dβ0
I(Yi ≥ u))
}]
,
which is a sum of independent and identically distributed samples. Thus H2(β0) converges
to a constant vector, C, that
C = E
[
dUi(β0)
dβ0
]
. (3.27)
From Equation (3.13), we can write H3(β0) as
H3(β0) = n
− 1
2
n∑
i=1
ψi(β0|Yi, Xi,Wi, Vi)
= n−
1
2
n∑
i=1
−E[l′′(β0|Yi, Xi,Wi, Vi)]−1{l′(β0|Yi, Xi,Wi, Vi)}T . (3.28)
As sample size goes to infinity, Equation (3.28) can be written as
n
1
2
n∑
i=1
−E[l′′(β0|Yi, Xi,Wi, Vi)]−1{l′(β0|Yi, Xi,Wi, Vi)}T
= n
1
2 − E[L′′(β0)]−1L′(β0)T , (3.29)
where L′(β0) is the score function for β0 that converges to a normal distribution with mean
zero and variance I(β0), which is the corresponding expected Fisher information matrix, and
−E[L′′(β0)]−1 equals [I(β0)]−1. So Equation (3.29) converges to a normal distribution with
mean zero and variance
σH3 = [I(β0)]
−1. (3.30)
To sum up, when n goes to infinite, the first term in Equation (3.18) converges to a
normal distribution, the second term also converges to a normal distribution since it becomes
a product of a constant and a normally distributed variable, and the third term converges
to zero since op(n) = nop(1) converges to zero. These three terms are not correlated with
each other. Therefore, n
1
2 (µˆ− µ) is asymtotically normally distributed with mean zero and
variance
σH1 + CσH3C
T , (3.31)
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where the form of σHi , C, and σH3 are showed in Equations (3.25), (3.27), and (3.30),
respectively. And this variance can be estimated by
ˆσH1 +H2(βˆ) ˆσH3H2(βˆ)
T . (3.32)
3.4 SIMULATION STUDIES
We evaluate the performance of our proposed mean quality adjusted lifetime estimator and
its corresponding variance estimator in a number of simulation studies. We generate the
quality of life score Wij for individual i at time tij from the following mixed effects model,
Wij = β0 + β1tij + b0i + b1itij + eij, (3.33)
bi =

b0i
b1i
 ∼ N (0,Σ), eij ∼ N (0, σ2),
where β0 = 2, β1 = −3, Σ =

σ11 σ12
σ21 σ22
 =

1 0
0 0.5
, σ = 1 and assume 10 measure-
ments for each individual at time ti = {tij, j = 1, 2, . . . , 10} = {1, 2, . . . , 10}. Considering the
dependency between the quality of life score and the event time, the following accelerated
failure time model is used to generate the survival data,
T0 =
∫ Ti
0
exp {α(β0 + β1t) + ηV } dt, (3.34)
where T0 is the baseline survival time, which is the survival time for an individual with all
covariates equal to zero, follows a weibull distribution with a shape parameter a = 1.5 and a
scale parameter b = 80, α = −0.2, f(t; β) = β0+β1t is the function of the population mean of
the quality of life score with β0 and β1 specified the same as in Model (3.33), and η = 1. We
consider 3 settings for the baseline covariate V in Model (3.34): (i) V = V1, where V1 follows
a binomial distribution with probability p = 0.5; (ii) V = V2, where V2 follows a standard
normal distribution; (iii) V includes both V1 and V2 with corresponding coefficient η1 and
36
η2, where V1 and V2 follow distributions as specified before. For each survival model, we
generate uncensored survival data with known β for a very large population (n=10000000)
first. The truncation time, L, is chosen to be the third quartile of the survival time of this
large population. This helps to make sure that a certain proportion of the population are still
followed after L in our simulation studies. Then the true mean of quality adjusted lifetime
for a restricted time period [0, L] is calculated as the average of the quality adjusted lifetime
defined as
Ui =
∫ Ti
0
logit−1{q(β0 + β1t)}dt, (3.35)
where q = 0.001 is a scale parameter. The censoring time Ci is generated from weibull
distributions with shape and scale parameters chosen appropriately such that the resulting
censoring proportion is about 20% and 40% . In order to more efficiently make use of all
available information, we estimate β and the variance of its estimator by applying the joint
modelling technique to Models (3.33) and (3.34). Then the proposed estimator of the mean
quality adjusted lifetime is obtained by Equation (3.9) with βˆ being the point estimator of
β, and its asymptotic variance is estimated by Equation (3.32). When β is assumed to be
known, the asymptotic variance of our proposed estimator can be calculated by Equation
(3.26).
We carry out the simulation studies under 8 scenarioes using survival models with differ-
ent baseline covariates as specified in Tables 6 and 7. In order to investigate the robustness
of our method to model misspecification, we fit survival models with a list of covariates
different from the true model and compare the results with that of the correct model. We
conducted 500 simulations under each setting with sample sizes N=200, 400, and 800.
The proposed estimators for the mean QAL have minimal biases (< 0.02) under all
settings. The bias decreases with increasing sample size. The average of the estimated
standard errors are very close to the means of the empirical standard derivations of the mean
QAL based on 500 simulation samples. The coverage probabilities of the 95% confidence
intervals are at nominal level. The biases of the proposed estimator increase slightly when
the survival models are misspecified, but still remain small, especially when the sample size
is large. In summary, the proposed estimator for the mean QAL is approximately unbiased.
Its asymptotic variance formula yields accurate results.
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3.5 CONCLUSION AND DISCUSSION
In this chapter, we propose an estimator for the mean quality adjusted lifetime with a
continuous quality of life function. This estimator takes into account the continuity of
people’s health experience, and thus better summarizes the quantitative and qualitative
health aspects of people. With the help of well-developed quality of life scales, we are able
to describe people’s continuously changing health status by the trajectory of quality of life
score defined as our quality of life function. We realize the possible biases that might be
introduced by directly using the scores since the measurement is usually taken infrequently
and with error during the course of studies. In order to avoid this bias and given the
dependency between the quality of life status and the survival time, we consider jointly
modeling the quality of life score and the survival time using a mixed effects model and a
survival model as an ideal approach. We find the most appropriate values for the parameters
in the quality of life function by maximizing the joint likelihood, and then calculate the
quality adjusted lifetime by integrating the quality of life function over the observed survival
time. We suggest an estimator for the mean quality adjusted lifetime in a restricted time
period for right censored data, and derive its asymptotic variance. The simulation studies
show that our proposed estimator is unbiased and robust to model misspecification, and our
variance formula is correct. Our proposed estimator enables a comprehensive comparison
of treatments that may benefit people’s health in different ways or be applied to different
populations in clinical trials.
However, the consistency of our estimator depends on the assumption the censoring
time is independent of the survival time and the health experience. In situations that the
censoring depends on the survival time, we may consider the use of imputation techniques
for missing data, sensitivity analyses to mimic best and worst-case scenarios and use of the
drop-out event as a study end-point [46]. If the censoring depends on the health experience,
theoretically we can model the actual distribution of the censoring time and substitute the
Kaplan-Meier estimator for the censoring time in the denominator of our proposed estimator
with it. This should help to maintain the good performance of the proposed estimator. These
studies will be subjects of future research.
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Table 6: Simulation results for the estimator of the mean quality adjusted lifetime, µˆ, and
its asymptotic standard error for 20% censored data based on 500 replications.
True model covariate distribution True µ N Baseline covariate (Fit) Bias(µˆ) SD(µˆ) MeanSE 95% CP
V1 ∼ BIN(0.5) 8.577 200 Known β 0.003 0.097 0.099 0.950
Binary 0.003 0.096 0.099 0.954
Continuous 0.010 0.100 0.099 0.946
400 Known β 0.007 0.072 0.070 0.922
Binary 0.007 0.072 0.070 0.926
Continuous 0.015 0.078 0.079 0.921
800 Known β 0.001 0.050 0.050 0.936
Binary 0.001 0.050 0.050 0.942
Continuous 0.006 0.053 0.054 0.938
V2 ∼ N(0, 1) 8.980 200 Known β 0.006 0.109 0.109 0.940
Continuous 0.007 0.108 0.109 0.934
Binary 0.011 0.111 0.113 0.933
400 Known β 0.011 0.077 0.078 0.942
Continuous 0.009 0.087 0.091 0.956
Binary 0.013 0.091 0.096 0.951
800 Known β <0.001 0.053 0.055 0.950
Continuous 0.001 0.060 0.066 0.972
Binary 0.009 0.063 0.066 0.961
V1 and V 2 8.780 200 Known β 0.003 0.053 0.052 0.947
Binary and Continuous 0.003 0.054 0.055 0.946
Binary 0.012 0.057 0.056 0.939
Continuous 0.007 0.056 0.056 0.941
400 Known β 0.003 0.038 0.037 0.948
Binary and Continuous 0.003 0.038 0.040 0.955
Binary 0.014 0.042 0.043 0.952
Continuous 0.005 0.039 0.041 0.951
800 Known β 0.001 0.027 0.026 0.943
Binary and Continuous 0.001 0.028 0.031 0.973
Binary 0.009 0.031 0.033 0.955
Continuous 0.004 0.032 0.034 0.962
β0 = 2, β1 = −3, σ11 = 1, σ12 = σ21 = 0, σ22 = 0.5, σ = 1, and α = −0.2, η = 1, a = 1.5,
b = 80.
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Table 7: Simulation results for the estimator of the mean quality adjusted lifetime, µˆ, and
its asymptotic standard error for 40% censored data based on 500 replications.
True model covariate distribution True µ N Baseline covariate (Fit) Bias(µˆ) SD(µˆ) MeanSE 95% CP
V1 ∼ BIN(0.5) 8.577 200 Known β 0.008 0.109 0.111 0.952
Binary 0.009 0.108 0.113 0.954
Continuous 0.016 0.111 0.114 0.948
400 Known β 0.006 0.080 0.079 0.940
Binary 0.006 0.079 0.081 0.950
Continuous 0.016 0.082 0.084 0.944
800 Known β 0.002 0.056 0.056 0.948
Binary 0.002 0.056 0.059 0.960
Continuous 0.011 0.061 0.064 0.956
V2 ∼ N(0, 1) 8.980 200 Known β 0.009 0.123 0.124 0.948
Continuous 0.009 0.123 0.126 0.954
Binary 0.018 0.125 0.127 0.951
400 Known β 0.009 0.088 0.088 0.944
Continuous 0.009 0.087 0.091 0.956
Binary 0.014 0.092 0.094 0.952
800 Known β 0.001 0.061 0.062 0.958
Continuous 0.001 0.060 0.066 0.972
Binary 0.007 0.065 0.064 0.964
V1 and V 2 8.780 200 Known β <0.001 0.058 0.058 0.956
Binary and Continuous <0.001 0.059 0.061 0.962
Binary 0.015 0.062 0.064 0.958
Continuous 0.009 0.061 0.063 0.959
400 Known β 0.001 0.043 0.041 0.944
Binary and Continuous 0.001 0.044 0.044 0.954
Binary 0.013 0.053 0.049 0.948
Continuous 0.008 0.048 0.047 0.952
800 Known β 0.001 0.032 0.029 0.939
Binary and Continuous 0.001 0.033 0.034 0.960
Binary 0.008 0.038 0.036 0.952
Continuous 0.003 0.035 0.036 0.956
β0 = 2, β1 = −3, σ11 = 1, σ12 = σ21 = 0, σ22 = 0.5, σ = 1, and α = −0.2, η = 1, a = 1.5,
b = 80.
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